Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 68 of 68 results for early and locally advanced breast cancer

  1. ATEC system for vacuum-assisted breast biopsy (MIB43)

    NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system

  2. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  3. Developing NICE guidelines: the manual (PMG20)

    Developing NICE guidelines: the manual

  4. Reducing radiotherapy for some breast cancer patients is likely to have released thousands of appointments for the NHS without compromising safety, NICE finds.

    Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term and is now enshrined in NICE guidance.

  5. NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018

    An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.

  6. NICE final draft guidance adds further treatment option for triple-negative breast cancer

    NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.

  7. Price discount helps give green light for breast cancer drug pertuzumab

    NICE approves the third breast cancer drug is as many weeks as pertuzumab is recommended to shrink tumours in some people with breast cancer so surgery can take place.